SEC Company Response from Harpoon Therapeutics, Inc. (CIK 0001708493) — Apr 21, 2020
Harpoon Therapeutics, Inc. (CIK 0001708493)
Date: April 21, 2020 · CIK: 0001708493 · Accession: 0001193125-20-113692
AI Filing Summary & Sentiment
File numbers found in text: 333-237175
Letter
HARPOON THERAPEUTICS, INC.
131 Oyster Point Blvd, Suite 300
South San Francisco, CA 94080
April 21,
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Irene Paik
Re: Harpoon Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 13, 2020
File No. 333-237175
Acceleration Request
Requested Date: April 23, 2020
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-237175) (the “Registration Statement”) to become effective on April 23, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Division of Corporation Finance. The Registrant hereby authorizes each of Laura Berezin, Robert Phillips and Jonie Kondracki of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Laura Berezin of Cooley LLP at (650) 843-5128, Robert Phillips of Cooley LLP at (415) 693-2020 or Jonie Kondracki of Cooley LLP at (415) 693-2174.
[Signature page follows]
Very truly yours,
Harpoon Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP HARPOON THERAPEUTICS, INC. 131 Oyster Point Blvd, Suite 300 South San Francisco, CA 94080 April 21, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Irene Paik Re: Harpoon Therapeutics, Inc. Registration Statement on Form S-3 Filed March 13, 2020 File No. 333-237175 Acceleration Request Requested Date: April 23, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-237175) (the “Registration Statement”) to become effective on April 23, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Division of Corporation Finance. The Registrant hereby authorizes each of Laura Berezin, Robert Phillips and Jonie Kondracki of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Laura Berezin of Cooley LLP at (650) 843-5128, Robert Phillips of Cooley LLP at (415) 693-2020 or Jonie Kondracki of Cooley LLP at (415) 693-2174. [Signature page follows] Very truly yours, Harpoon Therapeutics, Inc. By: /s/ Georgia Erbez Georgia Erbez Chief Financial Officer cc: Gerald McMahon, Harpoon Therapeutics, Inc. Laura Berezin, Cooley LLP Robert Phillips, Cooley LLP Jonie Kondracki, Cooley LLP